KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Net Income (2016 - 2025)

Historic Net Income for Rigel Pharmaceuticals (RIGL) over the last 16 years, with Q3 2025 value amounting to $27.9 million.

  • Rigel Pharmaceuticals' Net Income rose 12461.96% to $27.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $113.2 million, marking a year-over-year increase of 281795.93%. This contributed to the annual value of $17.5 million for FY2024, which is 16961.06% up from last year.
  • As of Q3 2025, Rigel Pharmaceuticals' Net Income stood at $27.9 million, which was up 12461.96% from $59.6 million recorded in Q2 2025.
  • In the past 5 years, Rigel Pharmaceuticals' Net Income registered a high of $59.6 million during Q2 2025, and its lowest value of -$27.4 million during Q1 2022.
  • For the 5-year period, Rigel Pharmaceuticals' Net Income averaged around $781473.7, with its median value being -$5.7 million (2023).
  • Its Net Income has fluctuated over the past 5 years, first tumbled by 16953.21% in 2022, then skyrocketed by 588766.99% in 2025.
  • Over the past 5 years, Rigel Pharmaceuticals' Net Income (Quarter) stood at -$22.6 million in 2021, then soared by 106.2% to $1.4 million in 2022, then plummeted by 47.39% to $737000.0 in 2023, then soared by 1843.28% to $14.3 million in 2024, then surged by 94.81% to $27.9 million in 2025.
  • Its last three reported values are $27.9 million in Q3 2025, $59.6 million for Q2 2025, and $11.4 million during Q1 2025.